Adam Kibel, MD

Adam S. Kibel, MD is Chief of Urologic Surgery at both the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is Elliot Carr Cutler Professor of Surgery at Harvard University School of Medicine, Chairman of the Harvard Program in Urology Residency Program (Longwood) and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.
Dr. Kibel’s practice focused on minimally invasive treatments for urologic cancers. With over 200 peer reviewed publications, Dr Kibel’s research focuses on the identification of molecular markers of urologic tumors, integration of systemic agents earlier in the disease process and improved imaging of patients with urologic malignancies. His research has been supported by the National Cancer Institute, Prostate Cancer Foundation, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:MyovantMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:ExlexisMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Insight DiagnositicsMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:AstraZenecaMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:BayerMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:General ElectricMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Other (Oncology)Ineligible company:advantageneMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:MerckMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Other (Specialty Not Specified)Ineligible company:Bristol-Myers SquibbMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:JanssenMitigation strategy:Peer reviewDate reviewed:09/20/2022